Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

RECRUITING

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Lead Sponsor:

Maria Sklodowska-Curie National Research Institute of Oncology

Collaborating Sponsors:

KCRI

Conditions:

Nasopharyngeal Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Multicentre , non-randomized, prospective clinical trial to assess efficacy of Nivolumab in treatment of nasopharyngeal cancer who progressed during or after platinum-based chemotherapy . Patients dis...

Eligibility Criteria

Inclusion

  • Age \> 18 years old
  • Histological or cytological documentation of squamous cell carcinoma.
  • Primary tumor location in nasopharynx
  • Previous, documented failure on platinum-based chemotherapy or progression of the disease during platinum-based chemotherapy
  • Tumor recurrence (local or nodal) or generalization (metastasis) occurence during or within 6 months after previous platinum-based chemotherapy
  • ECOG(Eastern Cooperative Oncology Group) performance scale 0-1
  • Participant is willing and able to give informed consent for participation in the study and agrees to undergo all follow up visit and planned procedures.

Exclusion

  • Known active central nervous system metastases.
  • Presence of renal insufficiency defined as eGFR(estimated glomerular filtration rate) \< 30 ml/min/m2
  • Presence of liver disfunction, defined as level of AST(aspartate aminotransferase) and /or ALT(alanine aminotransferase) \> 2,5 x ULN(upper limits of normal) (\> 5 x ULN in patients with documented liver metastases); total bilirubin \> 1,5 xULN ( bilirubin \> 1,5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \< 35%) or albumin \< 2,5 g/dL
  • Abnormalities in blood count such as: hemoglobin \< 9 g/dl, platelets \< 100 x 109 /L, Absolute Neutrophil Count (ANC) \<1,0 x 109 /L
  • Ejection fraction in echocardiography \< 50%
  • History of active autoimmune diseases except for type I diabetes, hypothyroidism (treated only with hormone supplementation), psoriasis, albinism.
  • Patient with diagnosed mental disorder preventing, in Investigator's opinion, from participating in a clinical trial.
  • Pregnancy or breastfeeding.
  • Female with childbearing potential or male participant with female partner of childbearing potential, who is unwilling or unable to use an acceptable method of contraception to avoid pregnancy throughout the entire clinical trial period and for 5 months after the end of treatment (last infusion)
  • Prior therapy with an anti-PD-1/L1/L2 and/or anti-ICOS directed agent
  • Patient is currently participating in another clinical trial.
  • Active infection, which significantly affects the patient's clinical condition and requires treatment.
  • Patient with prior bone marrow or solid organ transplantation.
  • Patient requires immunosuppressive agents, including steroids (daily dose of prednisone or equivalent \> 10 mg)
  • Known immunodeficiency including HIV/AIDS(human immunodeficiency virus/acquired immunodeficiency syndrome) infection.
  • Patient received any live vaccine within 28 days before enrollment.
  • Heart Failure - NYHA(New York Heart Association functional classification system) III or IV
  • Coexistence of active malignant tumor or history of malignant tumor after radical treatment with disease-free period \> 2 years, except: cervical cancer in situ/ basocellular skin cancer/prostate cancer, after radical treatment.
  • Other comorbidities symptoms or conditions that in Investigator's judgement prevent patient from participation in clinical trial.

Key Trial Info

Start Date :

August 26 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT04875611

Start Date

August 26 2021

End Date

December 31 2025

Last Update

April 24 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Klinika Hematologii z Pododziałem Chorób Naczyń Uniwersyteckiego Szpitala Klinicznego w Białymstoku

Bialystok, Poland

2

Klinika Hematologii i Transplantologii Gdańskiego Uniwersytetu Medycznego

Gdansk, Poland

3

Klinika Transplantacji Szpiku i Onkohematologii Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Oddział w Gliwicach

Gliwice, Poland, 44-101

4

Klinika Hematologii i Transplantacji Szpiku, Świętokrzyskie Centrum Onkologii

Kielce, Poland